LAS VEGAS, April 12, 2022 — Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, reported preliminary unaudited results for the first quarter ended March 31, 2022.
Net revenue for the first quarter is expected to total more than $489,000, up 187% over the same year-ago quarter, and keeps full year outlook on track for revenue to double to more than
“Our record top-line for a first quarter resulted primarily from expansion of direct-to-consumer channels, including a four-fold increase in recurring revenue from product subscriptions,” stated Duke Pitts, president of Healthy Extracts. “We also expect this strong performance to drive our first-ever positive net income quarter.”
Over the past year, the company established a solid foundation for addressing the fast-growing brain and heart health supplement market, including key acquisitions and successful clinical studies that support its products’ health benefit claims.
“We believe the progress we have made, particularly with expanding our sales channels and portfolio of clinically proven natural products, keeps us on course for our earlier guided 100% sales growth in 2022,” added Duke. “Together with our continued focus on building our recurring revenue stream from subscriptions, we anticipate a continued strengthening of our shareholder value throughout the year.”
The preliminary unaudited results are estimates only and are subject to revision until the company reports its financial results for the first quarter ended March 31, 2022, which it expects to report in May.
About Healthy Extracts “Live Life Young Again”
Healthy Extracts Inc. is a platform for developing or acquiring science-forward, clinically proven, plant-based proprietary products in select high-growth categories within the multibillion-dollar nutraceuticals market.
The company’s subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement containing Citrus Bergamot SuperFruit™. This superfruit is known to have the highest quality and concentration of polyphenols and flavonoids, and with healthy heart benefits backed by more than 17 clinical studies.
UBN KETONOMICS® proprietary formulations have been clinically shown to improve brain health, including memory, cognition, focus and neuro-energy. UBN is pursuing intellectual property license opportunities for monetizing its IP portfolio of multiple issued and pending patents.
For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com.
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K filed with the SEC on April 1, 2022, and future periodic reports filed with the SEC. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.
The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
Food and Drug Administration Disclosure
The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor’s advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.